Correlation Between Innate Pharma and Genfit
Can any of the company-specific risk be diversified away by investing in both Innate Pharma and Genfit at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Innate Pharma and Genfit into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Innate Pharma and Genfit, you can compare the effects of market volatilities on Innate Pharma and Genfit and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Innate Pharma with a short position of Genfit. Check out your portfolio center. Please also check ongoing floating volatility patterns of Innate Pharma and Genfit.
Diversification Opportunities for Innate Pharma and Genfit
0.36 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Innate and Genfit is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Innate Pharma and Genfit in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Genfit and Innate Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Innate Pharma are associated (or correlated) with Genfit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Genfit has no effect on the direction of Innate Pharma i.e., Innate Pharma and Genfit go up and down completely randomly.
Pair Corralation between Innate Pharma and Genfit
Assuming the 90 days trading horizon Innate Pharma is expected to generate 1.52 times more return on investment than Genfit. However, Innate Pharma is 1.52 times more volatile than Genfit. It trades about -0.01 of its potential returns per unit of risk. Genfit is currently generating about -0.02 per unit of risk. If you would invest 194.00 in Innate Pharma on December 30, 2024 and sell it today you would lose (8.00) from holding Innate Pharma or give up 4.12% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Innate Pharma vs. Genfit
Performance |
Timeline |
Innate Pharma |
Genfit |
Innate Pharma and Genfit Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Innate Pharma and Genfit
The main advantage of trading using opposite Innate Pharma and Genfit positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Innate Pharma position performs unexpectedly, Genfit can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genfit will offset losses from the drop in Genfit's long position.Innate Pharma vs. Genfit | Innate Pharma vs. Nanobiotix SA | Innate Pharma vs. Cellectis | Innate Pharma vs. AB Science SA |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Complementary Tools
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Fundamental Analysis View fundamental data based on most recent published financial statements |